UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule
13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of September 2025
Commission File Number: 001-37353
SCINAI IMMUNOTHERAPEUTICS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
EXPLANATORY
NOTE
Attached are the Company’s press release
providing a business update for the first half of 2025, condensed interim unaudited financial statements and a summary of its operating
and financial review and prospects, each as of June 30, 2025, furnished herewith as Exhibits 99.1, 99.2 and 99.3, respectively
This Report
on Form 6-K (including Exhibits 99.1, 99.2 and 99.3) is hereby incorporated by reference into the registrant’s Registration Statements
on Form S-8 (File No. 333-271293 and
File No. 333-239344)
and Form F-3 (File No. 333-274078 and
File No. 333-276767),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
Exhibit Index
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated September 2, 2025 |
| 99.2 |
|
Condensed Consolidated Unaudited Financial Statements as of June 30, 2025 |
| 99.3 |
|
Operating and Financial Review and Prospects as of June 30, 2025 |
| 101.INS |
|
Inline
XBRL Instance Document |
| 101.SCH |
|
Inline
XBRL Taxonomy Extension Schema Document |
| 101.CAL |
|
Inline
XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF |
|
Inline
XBRL Taxonomy Extension Label Linkbase Document |
| 101.LAB |
|
Inline
XBRL Taxonomy Extension Presentation Linkbase Document |
| 101.PRE |
|
Inline
XBRL Taxonomy Extension Definition Linkbase Document |
| 104 |
|
Cover
Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Scinai Immunotherapeutics Ltd. |
| |
|
|
| Date: September 2, 2025 |
By: |
/s/ Amir Reichman |
| |
|
Amir Reichman |
| |
|
Chief Executive Officer |
